Le Lézard
Classified in: Health
Subject: v

Sienna Announces June Dividend


MARKHAM, Ontario, June 15, 2018 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") (TSX:SIA) today announced a dividend of $0.075 per common share of the Company (each, a "Common Share") for the month of June 2018, representing $0.90 per Common Share on an annualized basis.

The dividend will be payable on July 13, 2018 to shareholders of record as at June 29, 2018. 

The Company's dividends are designated as eligible dividends for Canadian tax purposes in accordance with subsection 89(14) of the Income Tax Act (Canada), and any applicable corresponding provincial and territorial legislation.

Sienna has a Dividend Reinvestment Plan (the "DRIP") which allows eligible shareholders of the Company to direct that their cash dividends be reinvested in additional Common Shares.  Common Shares issued pursuant to the DRIP are issued from treasury at a 3% discount from the market price. Participation in the DRIP is optional and shareholders who do not wish to participate in the plan will continue to receive cash dividends.  A complete copy of the DRIP is available under the Investors section of the Company's website.

ABOUT SIENNA SENIOR LIVING

Sienna Senior Living Inc. (TSX:SIA) is a leading seniors' living provider with 85 seniors' living residences in key markets in Canada. Sienna offers a full range of seniors' living options, including independent and assisted living, long-term and residential care, and specialized programs and services. Sienna also provides expert management services. Sienna is committed to national growth, while driving long-term value for shareholders. The Company's approximately 12,000 employees are passionate about helping residents live fully every day, and were the driving force behind Sienna being named one of Canada's Most Admired Corporate Cultures in 2017. For more information, please visit www.siennaliving.ca.

CONTACT:

Nitin Jain
Chief Financial Officer & Chief Investment Officer
(905) 489-0787
[email protected]


These press releases may also interest you

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...

at 07:30
During an awards ceremony to present the 2024 list of Best Workplacestm in Canada, Great Place to Work® announced the 50 Best Workplacestm in Canada with 100-999 employees....

at 07:05
At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying...

at 07:00
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...

at 07:00
R&D Leader and software architect with more than three decades of experience designing, developing,...

at 07:00
Gordian Biotechnology, an in vivo drug discovery and development...



News published on and distributed by: